Evidence map›Paper›PMID 32873330›Full record

ArticleSystematic reviews2020

GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and meta-analysis protocol.

Caroul Chawar, Alannah Hillmer, Stephanie Sanger, Alessia D'Elia, Balpreet Panesar, Lucy Guan, Dave Xiaofei Xie, Nandini Bansal, Aamna Abdullah, Flavio Kapczinski and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Systematic reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Caroul ChawarNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Alannah HillmerNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Stephanie SangerHealth Sciences Library, McMaster University, Hamilton, ON, Canada.
Alessia D'EliaNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Balpreet PanesarNeuroscience Graduate Program, McMaster University, Hamilton, ON, Canada.
Lucy GuanDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Dave Xiaofei XieDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Nandini BansalDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Aamna AbdullahDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Flavio KapczinskiDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Guillaume ParePopulation Health Research Institute, Hamilton, ON, Canada.
Lehana ThabanePopulation Health Research Institute, Hamilton, ON, Canada.
Zainab SamaanDepartment of Psychiatry and Behavioural Neurosciences, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada. samaanz@mcmaster.ca.ORCID 0000-0002-5974-9361

Funding

CIHR PJT-156306
6 · The paper itself

Abstract

backgroundThe burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance.

methodsThe databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible. DISCUSSION: This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes. SYSTEMATIC REVIEW REGISTRATION: This systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration ID CRD42020169121).

Indexed as

Analgesics, OpioidGenome-Wide Association StudyOpioid-Related DisordersHumansMeta-Analysis as TopicNorth AmericaSystematic Reviews as TopicTreatment OutcomeAnalgesics, OpioidGenome-wide associationMedication-assisted treatmentOpioid usePharmacogeneticsProtocolSNPSystematic reviewTreatment response

Identifiers

PMID32873330
PMCPMC7466496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.